ArticleDrug design, development and therapy2025
Analysis of Menopausal Hormone Therapy to Chinese Patients with Menopausal Syndrome: A Real-World Retrospective Study from Chinese Hospitals.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Kuntai capsules with low-dose Femoston for perimenopausal syndrome: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Antihypertensive drug use for hypertensive disorders of pregnancy in hospitals across nine Chinese cities: a real-world data study.BMC pregnancy and childbirth · 2026Article
- Epidemiology, early detection, and management of breast cancer in China: A comprehensive review.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate and analyse the changing trends in the use of menopausal hormone therapy (MHT) for patients with menopausal syndrome (MPS) in hospitals in nine Chinese cities from 2019 to 2023 and to provide an evidence base for the rational clinical use of MHT. Methods: Data on the use of MHT by patients with menopausal syndrome were collected and a trend analysis was conducted, including trends in the number of prescriptions, patient age, total prescription amount, average prescription amount, defined daily doses (DDDs), defined daily cost (DDC), and drug rank ratio (B/A). Results: From 2019 to 2023, the prescriptions of MPS patient were concentrated in East China and North China, with an average age of 48.22±5.94 years. In a span of five years, the number of prescriptions increased by 86.08%, the total prescription amount increased by 126.58%, and the average prescription amount increased by 21.76%. The B/A ratios for estradiol/estradiol dydrogesterone and tibolone were both determined to be 1, thus indicating that the sales amounts and DDDs of these two drugs were in good agreement and that the drug costs are reasonable. Conclusion: From 2019 to 2023, the number of MPS patients and the total number of treatment drug prescriptions in nine cities throughout the country demonstrated an increasing trend. The estradiol/estradiol dydrogesterone and tibolone were the main sex hormone drugs that were used to treat MPS. The state's abolition of the drug price addition policy and the organization of centralized drug procurement in some areas had alleviated the financial burdens on patients to a certain extent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.